“Mindray Medical saw growth in performance in the first half of the year, and its business layout resonated deeply with healthcare reform policies.”

In the first half of 2026, Mindray Medical achieved revenue of 17.747 billion yuan, a year-on-year increase of 6.00%; its net profit attributable to the parent company was 4.797 billion yuan, a year-on-year increase of 7.22% after deducting exchange rate gains and losses. In the second quarter alone, revenue reached 9.395 billion yuan, a year-on-year increase of 10.45%. The net cash flow from operating activities reached 3.496 billion yuan, a year-on-year increase of 44.00%. By region, international business revenue was 9.471 billion yuan, a year-on-year increase of 13.67%; domestic market revenue was 8.276 billion yuan, a slight decrease of 1.61% year-on-year, with the decline narrowing. The company expects domestic business to achieve positive growth for the whole year. At the policy level, three major healthcare reform policies were implemented in the first half of 2026: AI-assisted diagnosis was included in the national medical insurance catalog, the DRG/DIP 3.0 scheme will be introduced soon, and the three-year action plan for improving the quality of primary healthcare was fully launched. Mindray’s “Qiyuan Ecosystem” severe illness large model has been installed in over 40 hospitals, with an accuracy rate of over 90% for inspection large models, and ultrasonic AI large models can save approximately 20 minutes per examination.